Feng Chi Biotech Corp.

TPEX:6744 Stock Report

Market Cap: NT$311.1m

Feng Chi Biotech Valuation

Is 6744 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6744 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6744 (NT$20.2) is trading below our estimate of fair value (NT$24.33)

Significantly Below Fair Value: 6744 is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6744?

Key metric: As 6744 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 6744. This is calculated by dividing 6744's market cap by their current earnings.
What is 6744's PE Ratio?
PE Ratio16.1x
EarningsNT$19.28m
Market CapNT$311.08m

Price to Earnings Ratio vs Peers

How does 6744's PE Ratio compare to its peers?

The above table shows the PE ratio for 6744 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average48.8x
6615 Sofiva GenomicsLtd
41.3xn/aNT$870.2m
6518 Concord Medical
18.8xn/aNT$883.3m
6665 Healthconn
86.8xn/aNT$952.4m
6879 TCI GENE
48.4xn/aNT$1.3b
6744 Feng Chi Biotech
16.1xn/aNT$311.1m

Price-To-Earnings vs Peers: 6744 is good value based on its Price-To-Earnings Ratio (16.1x) compared to the peer average (48.8x).

Price to Earnings Ratio vs Industry

How does 6744's PE Ratio compare vs other companies in the Asian Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
6744 16.1xIndustry Avg. 21.0xNo. of Companies46PE01632486480+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 6744 is good value based on its Price-To-Earnings Ratio (16.1x) compared to the Asian Healthcare industry average (21x).

Price to Earnings Ratio vs Fair Ratio

What is 6744's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6744 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio16.1x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 6744's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Universal Vision Biotechnology

NT$17.8b

Operates a chain of eye care clinics in Taiwan and China.

3218

NT$210.50

7D

-4.1%

1Y

-25.1%

Hi-Clearance

NT$6.2b

Supplies medical devices for the renal, cardiac, radiation, dental, oral surgery, and metabolism markets in Taiwan.

1788

NT$138.50

7D

-0.4%

1Y

1.5%

Ma Kuang Healthcare Holding

NT$1.3b

An investment holding company, provides medical services in Taiwan and internationally.

4139

NT$30.35

7D

1.0%

1Y

-19.1%